On June 8, DexCom rose 5.27% in regular trading, reaching $77.13 per share with trading volume of approximately $75.92 million. The rally was driven by the release of landmark clinical data from the company's Connect study and multiple analyst target price upgrades.

DexCom published the latest Connect study results confirming that its G7 continuous glucose monitoring system, when combined with GLP-1 receptor agonists, achieved a 1.4% reduction in HbA1c versus just 0.2% in the control group. The G7 system also demonstrated significant clinical benefits when paired with metformin and SGLT2 inhibitors, providing the strongest evidence to date supporting CGM use among non-insulin-treated type 2 diabetes patients. The six-month extension phase of the randomized controlled trial is currently underway.

On the analyst front, Stifel raised its price target from $85 to $90 maintaining a Buy rating, while Mizuho lifted its target from $75 to $85 with an Outperform rating. The average analyst price target stands at $83.67. These upgrades followed DexCom's presentations at the ADA Scientific Sessions emphasizing CGM value across all diabetes populations and the company's push toward early intervention and preventive care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)